2024
DOI: 10.1007/s12032-024-02300-0
|View full text |Cite
|
Sign up to set email alerts
|

Selective targeting or reprogramming of intra-tumoral Tregs

Keywan Mortezaee
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 90 publications
0
1
0
Order By: Relevance
“…[7][8][9][10][11] Intratumoral Treg suppresses antitumor T cell responses and thus resists the effects of immune checkpoint inhibitor therapy. [12,13] Antibodies against T cell immunoreceptors with Ig and ITIM domains (TIGIT), one of the immune checkpoint molecules, improve the effectiveness of PD-L1 antibodies by suppressing Treg. [14] Therefore, the development of immunotherapy targeting Treg is expected.…”
Section: Introductionmentioning
confidence: 99%
“…[7][8][9][10][11] Intratumoral Treg suppresses antitumor T cell responses and thus resists the effects of immune checkpoint inhibitor therapy. [12,13] Antibodies against T cell immunoreceptors with Ig and ITIM domains (TIGIT), one of the immune checkpoint molecules, improve the effectiveness of PD-L1 antibodies by suppressing Treg. [14] Therefore, the development of immunotherapy targeting Treg is expected.…”
Section: Introductionmentioning
confidence: 99%